Eco R1 Capital, LLC Argenx Se Transaction History

Eco R1 Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$338.91 - $506.01 $102 Million - $152 Million	300,997 New	300,997 $115 Million
Q3 2022 Nov 14, 2022	SELL	$343.2 - $395.75 $36.9 Million - $42.5 Million	-107,473 Reduced 85.98%	17,527 $6.19 Million
Q1 2022 May 16, 2022	BUY	$254.45 - $351.06 $31.8 Million - $43.9 Million	125,000 New	125,000 $39.4 Million
Q1 2020 May 15, 2020	SELL	$108.83 - $165.23 $22 Million - $33.4 Million	-202,117 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$106.59 - $164.21 $35.1 Million - $54 Million	-329,048 Reduced 61.95%	202,117 $32.4 Million
Q3 2019 Nov 14, 2019	SELL	$113.31 - $150.51 $5.67 Million - $7.53 Million	-50,000 Reduced 8.6%	531,165 $60.5 Million
Q2 2019 Aug 14, 2019	SELL	$115.0 - $141.58 $28.1 Million - $34.5 Million	-243,922 Reduced 29.56%	581,165 $82.3 Million
Q4 2018 Feb 14, 2019	BUY	$63.81 - $109.82 $52.6 Million - $90.6 Million	825,087 New	825,087 $79.3 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Eco R1 Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Eco R1 Capital, LLC with notifications on news.